Organon & Co (OGN) concluded trading on Thursday at a closing price of $9.54, with 6.85 million shares of worth about $65.35 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -37.57% during that period and on May 29, 2025 the price saw a gain of about 4.26%. Currently the company’s common shares owned by public are about 259.96M shares, out of which, 258.99M shares are available for trading.
Stock saw a price change of 13.17% in past 5 days and over the past one month there was a price change of -27.51%. Year-to-date (YTD), OGN shares are showing a performance of -36.06% which decreased to -54.55% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.01 but also hit the highest price of $23.10 during that period. The average intraday trading volume for Organon & Co shares is 5.75 million. The stock is currently trading 7.32% above its 20-day simple moving average (SMA20), while that difference is down -16.29% for SMA50 and it goes to -38.91% lower than SMA200.
Organon & Co (NYSE: OGN) currently have 259.96M outstanding shares and institutions hold larger chunk of about 80.40% of that.
The stock has a current market capitalization of $2.48B and its 3Y-monthly beta is at 0.56. PE ratio of stock for trailing 12 months is 3.30, while it has posted earnings per share of $2.89 in the same period. Its PEG reads 2.78 and has Quick Ratio of 1.15 while making debt-to-equity ratio of 16.52. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OGN, volatility over the week remained 2.66% while standing at 8.21% over the month.
Stock’s fiscal year EPS is expected to drop by -6.05% while it is estimated to increase by 5.76% in next year. EPS is likely to grow at an annualized rate of 1.19% for next 5-years, compared to annual growth of -23.49% made by the stock over the past 5-years.
Coverage by JP Morgan stated Organon & Co (OGN) stock as an Underweight in their note to investors on September 06, 2024, suggesting a price target of $20 for the stock. On November 03, 2023, Goldman Downgrade their recommendations, while on September 21, 2023, Barclays Initiated their ratings for the stock with a price target of $28. Stock get an Outperform rating from Raymond James on March 16, 2023.
